[go: up one dir, main page]

WO2017040801A3 - Methods for making and using an immunoconjugate for the treatment of cancer - Google Patents

Methods for making and using an immunoconjugate for the treatment of cancer Download PDF

Info

Publication number
WO2017040801A3
WO2017040801A3 PCT/US2016/049932 US2016049932W WO2017040801A3 WO 2017040801 A3 WO2017040801 A3 WO 2017040801A3 US 2016049932 W US2016049932 W US 2016049932W WO 2017040801 A3 WO2017040801 A3 WO 2017040801A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
treatment
making
immunoconjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/049932
Other languages
French (fr)
Other versions
WO2017040801A2 (en
Inventor
Glen C. Macdonald
Rachelle L. DILLON
Arjune Premsukh
Jeannick Cizeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Viventia Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Bio Inc filed Critical Viventia Bio Inc
Publication of WO2017040801A2 publication Critical patent/WO2017040801A2/en
Publication of WO2017040801A3 publication Critical patent/WO2017040801A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to immunoconjugates having a ligand that binds to EpCAM and a toxin, and methods for making such immunoconjugates. Also encompassed by the invention are compositions and methods for the prevention or treatment of cancer.
PCT/US2016/049932 2015-09-02 2016-09-01 Methods for making and using an immunoconjugate for the treatment of cancer Ceased WO2017040801A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562213315P 2015-09-02 2015-09-02
US62/213,315 2015-09-02
US201562256388P 2015-11-17 2015-11-17
US62/256,388 2015-11-17

Publications (2)

Publication Number Publication Date
WO2017040801A2 WO2017040801A2 (en) 2017-03-09
WO2017040801A3 true WO2017040801A3 (en) 2017-05-04

Family

ID=58188425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/049932 Ceased WO2017040801A2 (en) 2015-09-02 2016-09-01 Methods for making and using an immunoconjugate for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2017040801A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2829283T (en) 2003-04-30 2017-09-08 Univ Zuerich Methods for treating cancer using an immunotoxin
CN105764925A (en) 2013-10-02 2016-07-13 维文蒂亚生物公司 Anti-EpCAM antibodies and methods of use
WO2016145349A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
US20220305066A1 (en) 2020-06-12 2022-09-29 Gencellmed Inc. Recombinant herpes simplex virus for multiple targeting and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
WO2014166002A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
WO2014166002A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA ET AL.: "Human Papillomavirus Type 18 E6 and E7 Genes Integrate into Human Hepatoma Derived Cell Line Hep G2", PLOS ONE, vol. 7, no. 5, 24 May 2012 (2012-05-24), pages 1 - 9, XP055379919 *

Also Published As

Publication number Publication date
WO2017040801A2 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
SA520411108B1 (en) Macrocyclic compounds and uses thereof
HK1254843B (en) Compositions comprising bacterial strains
MX2018013038A (en) Anti-il-33 antibodies, compositions, methods and uses thereof.
HK1254843A1 (en) Compositions comprising bacterial strains
HK1258098A1 (en) Methods of treating cancer
MX2019003938A (en) Spirocyclic compounds.
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
MX2017004715A (en) Humanized anti-ox40 antibodies and uses thereof.
MX2016016881A (en) Antibodies binding axl.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
WO2015120062A3 (en) Therapeutic compounds and compositions
MX2018000715A (en) Methods for treating cancer using apilimod.
WO2017040801A3 (en) Methods for making and using an immunoconjugate for the treatment of cancer
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
HK1249431A1 (en) Modified yeast-brachyury immunotherapeutic compositions
EP3847283A4 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
HK1252614A1 (en) Bicyclic compounds
MX379622B (en) Spirocyclic compounds
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
EA201992318A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN
WO2016167944A3 (en) Compositions and methods for treating autism
HK1255835A1 (en) Therapeutic compositions and methods for treating hepatitis b
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16842989

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16842989

Country of ref document: EP

Kind code of ref document: A2